EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

6. EMA corporate website

12th meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines

Presented by Marie-Agnes Heine and Christopher Gadd on 19 June 2024
Communication Department, Stakeholders and Communication Division

EMA corporate website: ema.europa.eu



EMA's main communication channel

- Guidance for pharmaceutical industry
- Information and news on medicines
- Information on who we are and what we do

Large, highly used website:

- More than 1,000,000 visitors per month
- 133,000 page views per day
- 24,000 downloads per day
- 90% search engine optimisation score

Transition to Drupal 10



Post-go-live improvements: highlights

- Search: aligning with user needs



Search

This search looks for keywords in all of the website's content. Search tips

Filter by

- Include documents

Categories

- Human (2068)
- Veterinary (330)

Medicine name

Show all +

Active substance / international non-proprietary name (INN) / common name

Show all +

Medicine

- Direct healthcare professional communication (117)
- Herbal medicines (199)
- Medicines (2068)
- Opinions on medicines for use outside EU (16)
- Orphan designations (2937)

Search results (2068)

Sort by Newest first

Remove all filters ● Medicines ● Human ●

Glyxambi

empagliflozin, linagliptin, Diabetes Mellitus, Type 2

Date of authorisation: 11 November 2016 **Revision:** 17

Last updated: 11 June 2024

Medicine Human Authorised

GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.)

budesonide, formoterol fumarate dihydrate, Asthma, Pulmonary Disease, Chronic Obstructive

Date of authorisation: 3 April 2020 **Revision:** 5

Last updated: 11 June 2024

Medicine Human Authorised

Pyzchiva

ustekinumab, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic ▼ Ⓑ

Date of authorisation: 19 April 2024

Last updated: 11 June 2024

Medicines

Select type of medicine

Medicines for human use | Medicines for veterinary use | Herbal products | All

Our Medicine finder above helps you find information on medicines authorised for human or veterinary use. You can find these by including the medicine's name or its active substance. It shows you information on centrally authorised medicines - medicines that EMA evaluated. You can also find information on herbal medicines.

Advanced search

Use our advanced search to make use of search filters that are designed to make your search more precise and for finding information on all types of medicine-related procedures, including **refused** or **withdrawn** medicines.

We also offer search tips to help optimise your search experience.

GO TO ADVANCED SEARCH →

Not able to find the medicine you are looking for?

Nationally authorised medicines

The medicine you are looking for may be authorised in individual Member States via **national procedures**, rather than centrally via EMA. Only medicines evaluated by EMA are available on this website.

You may not be able to obtain a complete list of available treatment options

Post-go-live improvements: highlights

- Search: aligning with user needs
  - Site-wide search
  - Medicine search
- Medicine pages: improving display of post-authorisation procedures



Revision	59

Assessment history

Changes since initial authorisation of medicine

Opdivo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (464.08 KB - PDF)
First published: 02/12/2015 **Last updated:** 11/06/2024 View

Opdivo-H-C-003985-II-0137 : EPAR - Assessment report - Variation
Adopted
Reference Number: EMA/225115/2024

English (EN) (4.7 MB - PDF)
First published: 11/06/2024 View

CHMP post-authorisation summary of positive opinion for Opdivo (II-137)
Adopted
Reference Number: EMA/CHMP/172162/2024

English (EN) (168.5 KB - PDF)
First published: 26/04/2024 View

Opdivo-H-C-003985-X-0132 : EPAR - Assessment report - Variation
Reference Number: EMA/93617/2024

English (EN) (4.36 MB - PDF)
First published: 04/04/2024 View

Opdivo-H-C-003985-II-0130 : EPAR - Assessment Report - Variation
Adopted
Reference Number: EMA/358599/2023

Back to top

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

OPDIVO

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
II/0137	Extension of indication to include OPDIVO in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma, based on interim results from study CA209901 (CheckMate901). This is a Phase 3, open-label,	25/04/2024	23/05/2024	SmPC and PL	Please refer to Scientific Discussion: Opdivo-H-C-3985-II-0137.

Post-go-live improvements: highlights

- Search: aligning with user needs
  - Site-wide search
  - Medicine search
- Medicine pages: improving display of post-authorisation procedures
  - Table of procedures on web pages
  - Documents, e.g. assessment reports, in corresponding rows
  - Replacing PDF document ‘procedural steps taken after authorisation’



Let us know what you need

Errors, specific issues, bugs, questions

Email newwebsite@ema.europa.eu

Include as many details as possible, e.g.:

- what you were trying to achieve
- what you did
- what happened
- URLs, screen shots, error messages, etc.

Suggestions, feedback, general concerns

EMA Website Key User Group

Being re-established this year

Representatives from industry associations

More news to come…

Thank you for your attention

Further information

newwebsite@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Telephone +31 (0)88 781 6000
Send us a question Go to www.ema.europa.eu/contact

Follow us on **@EMA_News**